ACC 2026 - Two randomised trials position TriClip TEER as a transformative option in TR, delivering significant reductions in heart failure hospitalisations and supporting earlier intervention in clinical practice.

Prof Erwan Donal (Hospital Pontchaillou of Rennes, Rennes, FR) joins us on-site at ACC 2026 to share the findings from two randomised trials (Tri.Fr and TRILUMINATE Pivotal) demonstrating superiority of TriClip TEER over medical therapy and marking a potential shift in tricuspid regurgitation management. 

Through this evidence, TriClip TEER has now showcased hard clinical endpoint benefit in the full randomized populations of two randomized trials. These findings challenge the perception of TR as a late-stage condition and prompt clinicians to reconsider the role of TriClip TEER and timing within the treatment pathway.

Interview Questions:

1. What is the significance of having two randomised trials confirming TriClip’s superiority over medical therapy?
2. How important is consistent TriClip benefit across both RCTs for the scientific community?
3. What impact can these results have on clinical practice?
4. How meaningful is the reduction in heart failure hospitalisations to daily practice?
5. What does less recurrent HFH mean for patients as well as the healthcare system?
6. How does delayed time to first HF hospitalisation change our understanding of the trajectory of TR and it's treatability?
7. Are we reaching a tipping point to redefine treatment expectations - from only Quality of Life benefit to HFH benefit?
8. Does this level of evidence finally close the gap between evidence and clinical adoption?
9. Given the strength and consistency of the data, how should clinicians think about TriClip in the treatment pathway today?
10. After this second RCT, where should TriClip sit within the treatment strategy for TR patients?
11. In light of these results, how should the scientific community rethink the timing of intervention for patients with TR?